Sensus Healthcare Inc (NAS:SRTS)

Q2 2025 Sensus Healthcare Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $5.35 (+0.38%)

Transcript 10-Q8-K

Key Points

Positve

Sensus Healthcare Inc (SRTS) reported a 27% increase in FDA treatment volume over Q1, indicating improved efficiency and growing patient awareness of SRT as a preferred treatment option.
The company broadened its US commercial footprint by appointing Radiation Oncology Systems as its primary distribution partner for the hospital-based oncology segment, which is expected to accelerate growth.
Sensus Healthcare Inc (SRTS) achieved MDSAP certification, providing immediate access to markets in Brazil, Canada, Japan, and Australia, enhancing international growth prospects.
The company delivered 19 SRT systems in Q2, including 4 to China, reflecting growing international demand for non-invasive therapeutic solutions.
Sensus Healthcare Inc (SRTS) is optimistic about the potential increase in reimbursement through a new SRT delivery code, which could significantly enhance its US commercial strategy.

Negative

Revenues for Q2 2025 were $7.3 million, down from $9.2 million in Q2 2024, primarily due to fewer capital system sales to a large customer.
Gross profit decreased to $2.9 million in Q2 2025 from $5.4 million in the prior year, with gross margin dropping to 39.7% from 58.7%, driven by lower sales and higher service costs.
The company reported a net loss of $1 million for Q2 2025, compared to a net income of $1.6 million in Q2 2024, reflecting higher operating expenses and lower revenue.
A proposed local coverage determination (LCD) by Medicare could limit reimbursement for ultrasound use with SRT 100 vision systems, causing a temporary stall in domestic sales momentum.
General and administrative expenses increased to $2 million in Q2 2025 from $1.6 million in Q2 2024, due to higher professional fees and compensation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRTS.OQ - Sensus Healthcare Inc
Q2 2025 Sensus Healthcare Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Census Healthcare 2nd quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the start key, followed by 0.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then what? On a touchstone phone.

To withdraw your question, please press star, then 2, please note this event is being recorded. I would now like to turn the conference over to Turth Patel with Alliance Advisors IR. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.